

Collaborative Testing Services, Inc. FORENSIC TESTING PROGRAM

## Manufacturer's Information Test No. 20-5803: DNA-Blood

Each sample pack consisted of two known bloodstains on FTA Micro cards (Items 1 & 2), and two questioned stains; one on clean pink fabric (Item 3) and one on clean, off-white fabric (Item 4). Participants were requested to analyze these items using their existing protocols.

SAMPLE PREPARATION: The stains in Items 1, 2, 3, and 4 were prepared using human whole blood which was either drawn into citric acid preservative bags or EDTA tubes. Items 1 (75  $\mu$ I) and 3 (50  $\mu$ I) were created using blood from the same female donor. Item 2 (75  $\mu$ I) was created using blood collected from a male donor. Item 4 (50  $\mu$ I) was created using blood from a female donor whose known standard was not provided. Stains from different sources were prepared at separate times and were packaged once they were thoroughly dried. Completed sample sets were stored at -20°C until shipment on April 22, 2020 following receipt of predistribution results.

SAMPLE SET ASSEMBLY: For each sample set, all four Items (1-4) were packed into separate envelopes and then placed together in a pre-labeled sample pack envelope. The sealed sample pack envelopes were then packaged in pre-labeled heat seal envelopes and sealed. This process was repeated until all of the sample sets were prepared.

VERIFICATION: All predistribution laboratories confirmed the manufacturer's expected associations. Consistent allelic results were reported for all STR and YSTR loci.

The information presented here is that received from the sample manufacturer. It presents details of the design specification for the test samples and/or details of how they were prepared. This information does not necessarily represent the answers that should or could be obtained from an examination of the sample. Final interpretation of the results should be deferred until the summary report is available.

## Manufacturer's Information, continued Test No. 20-5803: DNA-Blood

Amelogenin and STR Results													
	Results compiled from predistribution laboratories and a consensus of at least 10 participants.												
ltem	D1S1656	D2S1338	D2S441	D3S1358	D5\$818	D6S1043							
	D7\$820	D8\$1179	D10S1248	D12S391	D13S317	D16S539							
_	D18S51	D19S433	D21511	D22S1045	Amelogenin	CSF1PO							
	FGA	Penta D	Penta E	SE33	TH01	ΤΡΟΧ							
	vWA	DYS391	DY\$570	DYS576	Y Indel								
1	11,17.3	24,24	11,15	16,17	7,11	*							
	8,9	13,14	14,15	18,19	11,12	11,14							
	13,15	14,14.2	28,31.2	16,17	X,X	11,13							
	21,29	9,13	17,17	18,19	8,9.3	7,8							
	15,17	NM	NM	NM	NM								
2	15,16	17,19	11,12	16,17	12,13	*							
	9,10	14,15	13,13	20,21	12,13	9,10							
_	18,20	14,14	31.2,32.2	11,17	X,Y	12,13							
	24,26	10,12	8,12	17,20	7,9.3	9,10							
	16,16	10	17	17	2								
3	11,17.3	24,24	11,15	16,17	7,11	*							
	8,9	13,14	14,15	18,19	11,12	11,14							
_	13,15	14,14.2	28,31.2	16,17	X,X	11,13							
	21,29	9,13	17,17	18,19	8,9.3	7,8							
	15,17	NM	NM	NM	NM								
4	13,17	25,25	12,14	16,17	10,11	*							
	8,10	11,14	15,15	17,18	12,13	9,12							
	12,20	14.2,15	32,33.2	11,14	X,X	8,13							
	19,25	3.2,7	5,13	12,25.2	7,8	6,8							
	16,18	NM	NM	NM	NM								

## **YSTR Results**

Results compiled from predistribution laboratories and a consensus of at least 10 participants.													
ltem	DYF38751	DYS19	DYS385	DYS389-I	DYS389-II	DYS390	DYS391	DYS392	DYS393				
	DYS437	DYS438	DYS439	DYS448	DYS449	DYS456	DYS458	DYS460	DYS481				
	DYS518	DYS533	DYS549	DY\$570	DYS576	DYS627	DY\$635	DYS643	YGATAH4				
2	38,38	17	15,17	13	30	21	10	11	14				
	14	11	13	21	31	15	16	11	25				
	41	12	*	17	17	19	21	*	11				

\* Results were not received by a minimum of 10 participants for the loci indicated.

NM - Non-Male profile, YSTR results not expected.

The information presented here is that received from the sample manufacturer. It presents details of the design specification for the test samples and/or details of how they were prepared. This information does not necessarily represent the answers that should or could be obtained from an examination of the sample. Final interpretation of the results should be deferred until the summary report is available.